Sample size recalculation in three-stage clinical trials and its evaluation
Open Access
- 25 September 2024
- journal article
- research article
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 24 (1) , 1-15
Abstract
Background: In clinical trials, the determination of an adequate sample size is a challenging task, mainly due to the uncertainty about the value of the effect size and nuisance parameters. One method to deal with this uncertainty is a sample size recalculation. Thereby, an interim analysis is performed based on which the sample size for the remaining trial is adapted. With few exceptions, previous literature has only examined the potential of recalculation in two-stage trials. Methods: In our research, we address sample size recalculation in three-stage trials, i.e. trials with two pre-planned interim analyses. We show how recalculation rules from two-stage trials can be modified to be applicable to three-stage trials. We also illustrate how a performance measure, recently suggested for two-stage trial recalculation (the conditional performance score) can be applied to evaluate recalculation rules in three-stage trials, and we describe performance evaluation in those trials from the global point of view. To assess the potential of recalculation in three-stage trials, we compare, in a simulation study, two-stage group sequential designs with three-stage group sequential designs as well as multiple three-stage designs with recalculation. Results: While we observe a notable favorable effect in terms of power and expected sample size by using three-stage designs compared to two-stage designs, the benefits of recalculation rules appear less clear and are dependent on the performance measures applied. Conclusions: Sample size recalculation is also applicable in three-stage designs. However, the extent to which recalculation brings benefits depends on which trial characteristics are most important to the applicants.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (RA 2347/4-2, RA 2347/4-2, KI 708/4-2, KI 708/4-2, RA 2347/4-2)
- Charité - Universitätsmedizin Berlin
This publication has 23 references indexed in Scilit:
- Conditional power and friends: The why and how of (un)planned, unblinded sample size recalculations in confirmatory trialsStatistics in Medicine, 2022
- Optimal planning of adaptive two‐stage designsStatistics in Medicine, 2021
- A new conditional performance score for the evaluation of adaptive group sequential designs with sample size recalculationStatistics in Medicine, 2020
- A variational approach to optimal two‐stage designsStatistics in Medicine, 2019
- Optimal adaptive single-arm phase II trials under quantified uncertaintyJournal of Biopharmaceutical Statistics, 2019
- On the efficiency of adaptive sample size designStatistics in Medicine, 2018
- Adaptive sample size modification in clinical trials: start small then ask for more?Statistics in Medicine, 2015
- Adaptive increase in sample size when interim results are promising: A practical guide with examplesStatistics in Medicine, 2010
- Evaluating the adaptive performance of flexible sample size designs with treatment difference in an intervalStatistics in Medicine, 2007
- Adaptive Sample Size Calculations in Group Sequential TrialsBiometrics, 1999